The PubMed record describes a late‑phase clinical trial investigating low‑dose ruxolitinib for prevention of graft‑versus‑host disease (GVHD) in the setting of haploidentical haematopoietic stem‑cell transplantation (HSCT). The entry identifies this as a multicentre, open‑label, randomised, controlled phase 3 trial published in Lancet Haematology (Aug 2026). The source provided here does not include the trial abstract text or full manuscript content, and so detailed scientific rationale, prior evidence, or mechanistic discussion are not available in the accessible record.
The PubMed entry explicitly classifies the study as a multicentre, open‑label, randomised, controlled phase 3 trial. No further methodological detail (for example, randomisation ratio, stratification factors, blinding procedures beyond “open‑label,” number of centres, or geographic distribution beyond affiliating institutions) is provided within the displayed source text.
The publication lists Hengwei Wu and many co‑authors. Affiliations reported in the PubMed entry include the Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University research laboratories, the Li Ka Shing Faculty of Medicine at The University of Hong Kong, and several other Chinese haematology departments and hospitals. The corresponding author and contact email are reported in the record (yanminzhao@zju.edu.cn).
The available record confirms the clinical trial classification and phase but does not report key methodological elements such as participant eligibility criteria, sample size, conditioning regimens, graft sources or cell doses, concomitant immunosuppression, monitoring schedule, or statistical analysis plan. The PubMed display shows publication metadata (journal, volume, pages, DOI, PMID) but omits the trial abstract and outcome data in the content provided here.
The intervention under study is described as low‑dose ruxolitinib given for GVHD prevention after haploidentical HSCT. The PubMed record does not report the specific dose, dosing frequency, route, duration of prophylaxis, or comparator regimen used in the trial. Details about dose modifications, concomitant medications, or therapeutic drug monitoring are not present in the accessible text.
Although the record identifies the trial design and phase, the PubMed content provided here does not include primary or secondary endpoint definitions, numerical results for GVHD incidence, severity, survival outcomes, relapse rates, infection rates, adverse events, or statistical significance. Therefore no efficacy or safety outcomes can be extracted from this source alone. The absence of result data in the displayed record means readers must consult the full Lancet Haematology article to evaluate the trial’s findings.
The PubMed entry does not include authors’ interpretation, discussion, or conclusions about the clinical implications of the trial. It also does not state limitations addressed by the investigators or propose next steps. These narrative elements are typically found in the article abstract and discussion, which are not available in the provided content.
Publication details in the PubMed record:
The article is catalogued as a Clinical Trial in PubMed. The corresponding author’s email is listed in the entry. The PubMed display shows full author list and affiliations but does not include the abstract text or trial results in the excerpt provided here.
This PubMed entry documents a multicentre, randomised, controlled phase 3 evaluation of ruxolitinib as prophylaxis against GVHD in haploidentical HSCT recipients, signaling potential clinical importance for transplant practice. However, because the record shown here lacks the abstract and outcome data, clinicians, guideline authors, and researchers should retrieve and review the full Lancet Haematology article (DOI and PMID above) to assess methods, efficacy, safety, and applicability before changing practice or incorporating findings into recommendations.
Note: The source content available in this request consisted of the PubMed bibliographic entry and author/affiliation metadata. Specific trial methods, participant numbers, dosing, endpoints, results, and authors' conclusions were not reported in the provided text and therefore are not summarized here. For complete trial data, consult the full published article.